Development of an Antibody Dependent Enhancement(ADE) Assay to Support SARS-CoV2 Vaccine Development

Development of an Antibody Dependent Enhancement(ADE) Assay to Support SARS-CoV2 Vaccine Development

Contract Research

Information

We have developed antibody dependent enhancement (ADE) assay that is capable to evaluating capacity of antibodies to enhance secondary infection with SARS-CoV2 and provide valuable insights into the pathogenesis of this viral infection. This method can play a critical role in development of effective and safe vaccine. The assay is reliable, easy to execute, automation friendly and can be performed in a routine laboratory without the need for a BSL-3 laboratory.
CelerionCelerion, a leader in early clinical research services and clinical bioanalysis, is a global company with over 50 years of experience. Our unique combination of medical expertise, clinical operations experience and scientific excellence provides our customers with the guidance to make fast, accurate decisions about their drug development. Celerion has proven experience across a variety of vaccines, including different routes of administration, and patient populations. Our track record spans both preventive and therapeutic vaccines, subunit, and conjugates across all phases I-IV in more than 20 countries, 300 study centers and 4500 subjects.

Log in